. . "153168-05-9"@en . . . . . "Pleconaril binds to a hydrophobic pocket in viral protein 1, the major protein which comprises the capsid (the outer \"shell\") of picornaviruses. In enteroviruses, this prevents the virus from exposing its RNA, and in rhinoviruses it also prevents the virus from attaching itself to the host cell."@en . . . . . . ">99%"@en . . . . . "investigational"@en . . . . . . . . "Pleconaril"@en . "70% (oral)"@en . . "Investigated for use/treatment in upper respiratory infection."@en . . "# Webster AD: Pleconaril--an advance in the treatment of enteroviral infection in immuno-compromised patients. J Clin Virol. 2005 Jan;32(1):1-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15571999 # Florea NR, Maglio D, Nicolau DP: Pleconaril, a novel antipicornaviral agent. Pharmacotherapy. 2003 Mar;23(3):339-48. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12627933"@en . . . . "Pleconaril is an antiviral drug being developed by Schering-Plough for prevention of asthma exacerbations and common cold symptoms in asthmatic subjects exposed to picornavirus respiratory infections. Although the formulation used by Schering-Plough is a nasal spray, pleconaril is orally bioavailable, and is active against viruses in the Picornaviridae family, including Enterovirus and Rhinovirus."@en . . . . . . . .